Inspiringly, intervention of KRT19 in NSCLC cells enhanced anti-PD-1 immunotherapy efficiency by potentiating stronger antineoplastic responses of tumor-infiltrating cytotoxic CD8+ T cells (CTLs). Here, CD8A is linked to neoplasm.